Neptune Wellness Solutions Inc. (NEPT.TO)

Had trouble selling fishy tasting product but have resolved that. It is a bit of a concept stock. Be careful the valuation does not get out of whack with what they are able to deliver.

Owns 65% of Acasti Pharma (APO-X) which is in phase 2 trials of its drug CaPre. As those things come out, this is a market that historically has been as big as $20 billion of sales when Lipitor was pre-generic. Thinks this will be a category killer and will be taken over by one of the big pharmas once they get into phase 3 trials. Also have a small base business selling products that health-food stores call Neptune Krill Oil, which produces a nice cash flow.

They basically take krill (small shrimp), extracts the oil from them which is then used to reduce cholesterol in a natural way. There is a potential for combining their product with conventional statins for different methodology. Analysts are expecting this company will lose $0.15 for the Feb/14 year and another $0.02 a year later. Interesting opportunity but not profitable for the foreseeable future.

(Market Call Minute.) Table pounding buy. Have phase 2 data coming in the next 6 months which will catapult the stock up multiples.

In the Pharma space. Had been a long, long time in the making, trying to get some traction in the market with revenues and partners. Last year had a giant explosion at their plant. Now they have to rebuild and get investors re-interested in the game.

This company has had all kinds of uncertainties. Would have no interest in owning this one.